SCHIZOPHRENIA

This study tested whether a new version of a long-acting schizophrenia injection works the same as the current standard. 256 Chinese adults with stable schizophrenia received multiple doses of either the test or reference injection. The goal was to confirm the two medications rea…

This study tested the long-term safety and effectiveness of an experimental drug called KarXT for people with schizophrenia. Over 500 adults took the medication twice daily for up to 52 weeks. Researchers tracked side effects and how well the drug controlled symptoms over time.

This study tested whether a new drug, VHX-896, works like the existing drug iloperidone in 26 adults with schizophrenia or bipolar I disorder. Participants took both drugs in a crossover design to compare how the body processes them. The goal was to check if VHX-896 is a safe and…

This study looked at how well a new drug, SEP-363856, works and how safe it is for people with schizophrenia who switch from their current antipsychotic medication. About 100 clinically stable adults took part over 8 weeks. The main goal was to see how many stopped the study due …

This study tested whether a smartphone app called Quit on the Go helps people with serious mental illness (like bipolar disorder or schizophrenia) quit smoking better than standard methods. 343 smokers who wanted to quit were enrolled. The app was designed specifically for their …

This study tested whether a mindfulness-based education program could help people with schizophrenia stick to their medication and feel more mindful. 40 stable outpatients were split into two groups: one received the mindfulness program, the other got usual care. Results showed i…

This study tested whether adding a medication to a computer-based cognitive training program could improve thinking skills and daily function in people with schizophrenia or schizoaffective disorder. 68 adults completed the 10-week program, which involved up to 30 training sessio…

This study looked at the long-term safety and effectiveness of a drug called MP-214 in 42 adults with schizophrenia who were already taking other antipsychotic medications. The main goal was to see how many people had side effects. The study did not aim to cure schizophrenia, but…

This study tested a new long-acting olanzapine injection (TV-44749) against the standard oral olanzapine pill in 153 people with schizophrenia. The goal was to see if the shot delivers the same amount of medicine into the body and to check its safety. Participants received multip…

This study looked at the long-term safety and effectiveness of a drug called MP-214 in 125 people with chronic schizophrenia or elderly patients. The main goal was to track any side effects and see how well the drug worked over time. The results help doctors understand if MP-214 …

This study tested a new medicine called LB-102 in 359 adults with acute schizophrenia. Participants received either LB-102 or a placebo for 28 days while staying in the hospital. The main goal was to see if LB-102 reduces symptoms like hallucinations and confusion better than a p…

This study looked at the long-term safety of cariprazine in 310 children with schizophrenia, bipolar I disorder, or autism spectrum disorder over 52 weeks. The main goal was to track side effects and changes in health measures like lab tests, vital signs, and movement disorders. …

This early-stage study tested a new version of the schizophrenia medication risperidone given as a shot every three months. Researchers wanted to see how the drug moves through the body and if it is safe. 58 adults with stable schizophrenia who already take oral risperidone recei…

This study tested whether a 4-week ketogenic diet (very low carb, high fat) could improve brain network stability and thinking skills in 71 adults with schizophrenia or bipolar disorder. The diet aims to provide an alternative brain fuel (ketones) that may bypass problems with gl…

This study tested a new medication called MP-214 in 34 adults with schizophrenia. Participants took the pill once daily for 14 days at different doses to see if it was safe and how the body processed it. The goal was to gather early information on side effects and drug levels, no…

This study looked at the long-term safety of the drug brexpiprazole in teenagers aged 13 to 17 with schizophrenia. Researchers monitored side effects and how well the teens tolerated the medication over time. The goal was to understand if brexpiprazole is a safe maintenance treat…

This study tested a 'joint crisis plan' (SOS plan) for people with schizophrenia or schizoaffective disorder. The plan is created together by the patient, their family, and their healthcare team to guide care during a mental health crisis. The goal was to see if having this plan …

This study looked at whether changing antipsychotic medication can reduce symptoms of schizophrenia in people who are already on medication but still have symptoms. 219 adults with schizophrenia or schizoaffective disorder took part. Researchers measured how many people stopped t…

This study tested a new medicine called ITI-007 in 696 people with schizophrenia who were having a sudden worsening of symptoms. For 6 weeks, some received ITI-007, some a placebo, and some an active comparator. The main goal was to see if ITI-007 reduces symptoms like hallucinat…

This study tested a remote, personalized program to help people with schizophrenia who struggle to take their medication regularly. Thirty-six adults participated over 12 weeks, comparing the program to standard care. The goal was to see if the program was practical, well-liked, …

This study tested a long-acting injectable form of olanzapine (TV-44749) in 675 adults with schizophrenia. The goal was to see if a monthly shot could control symptoms better than a placebo. The trial lasted up to 61 weeks and measured changes in symptom severity using standard p…

This study tested a new drug called SEP-363856 to see if it is safe for people with schizophrenia to take over a long period. About 305 adults aged 18 to 65 with schizophrenia took part for up to 57 weeks. The main goal was to track any side effects or serious health issues that …

This study looked at how well Risperidone ISM works in real-world settings for people with schizophrenia who were hospitalized after a relapse. Researchers tracked 275 patients over 56 days to see if their symptoms and daily functioning improved. The goal was to understand the dr…

This study tested whether a gentle brain stimulation technique called tDCS can help people with schizophrenia whose symptoms don't fully improve with medication alone. 141 participants received either real or fake (placebo) stimulation over 5 days. The goal was to see if the real…

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. About 75 adults who completed a prior study took the new drug for up to 25 weeks. Researchers tracked side effects to see if the d…

This study looked at the long-term safety and tolerability of the drug MP-214 in 254 adults with schizophrenia. Participants had already completed an earlier study and continued taking MP-214 to see how well it was tolerated over time. The main focus was on tracking any side effe…

This study tested whether a higher dose of a long-acting injectable antipsychotic medication works better than the standard dose for people with schizophrenia or schizoaffective disorder. It involved 160 participants whose symptoms weren't well-controlled on their current medicat…

This study looked at whether aerobic exercise or computer-based cognitive training can help improve thinking and memory in people with schizophrenia. 58 adults with schizophrenia took part. The goal was to see which approach works better for sharpening mental skills.

This study tested a type of brain stimulation called theta-burst TMS to see if it can safely reduce negative symptoms (like lack of motivation) and improve thinking in people with schizophrenia. 76 adults with stable schizophrenia took part in a double-blind trial where some rece…

This study tested a program called Metacognitive Training (MCT) in 18 Taiwanese adults with schizophrenia, major depression, or bipolar disorder. Over four weeks, participants attended eight group sessions aimed at reducing unhelpful thinking patterns linked to symptoms like delu…

This study tested two smartphone-based programs (prescription digital therapeutics) in 464 adults and teens with schizophrenia who were already taking antipsychotic medication. The goal was to see if these apps could help reduce negative symptoms like lack of motivation and pleas…

This study looked at whether physical activity or virtual reality training works better for improving physical function, thinking skills, and quality of life in people with schizophrenia. 45 adults with schizophrenia took part in the completed trial. The goal is to find which app…

This study tested a new drug called MP-214 in 512 adults with acute schizophrenia symptoms. The goal was to see if MP-214 reduces symptoms like hallucinations and delusions better than a placebo over 6 weeks. Researchers measured changes using standard rating scales for symptom s…

This study tested whether a second course of a smartphone app could help reduce negative symptoms (like lack of motivation or pleasure) in people with schizophrenia who were already taking standard medication. 73 adults and older teens who had completed a previous app study took …

This early-stage study tested a new drug called MK-8189 in 53 adults with schizophrenia. The main goal was to see if the drug is safe and tolerable, and to check for any effects on heart rhythm. Participants received multiple doses to monitor side effects and how the drug behaves…

This study tested whether adding structured supportive psychotherapy to the medication risperidone helps improve thinking and reduce inflammation in people with schizophrenia. Forty-six men took part, with half receiving both therapy and medication, and the other half receiving m…

This study tested whether adding valbenazine to standard antipsychotic medication helps reduce schizophrenia symptoms in adults who still have symptoms despite treatment. 442 participants received either valbenazine or a placebo for 10 weeks. The main goal was to see if valbenazi…

This study tested whether adding curcumin (the active ingredient in turmeric) to the standard medication risperidone could improve quality of life and reduce inflammation in men with schizophrenia. 44 participants took either risperidone alone or risperidone plus curcumin for 8 w…

This study tested a noninvasive brain stimulation technique called transcranial random noise stimulation to see if it could reduce cravings in people with substance use disorder who also have other mental health conditions like ADHD, bipolar disorder, or schizophrenia. 225 adults…

This study tested whether patients with schizophrenia or schizoaffective disorder could improve their awareness of their illness by watching a video of themselves recorded during a severe episode. 60 patients participated, with half watching the video after they stabilized. The g…

This study tested a virtual reality (VR) program to help people with schizophrenia improve their social skills and daily functioning. 37 participants completed 12 weekly VR sessions that simulated real-life social situations. The goal was to see if this safe, controlled VR experi…

This study tested a daily tablet called iclepertin to see if it could improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo for 26 weeks while continuing their usual schizophrenia medication. Researc…

This study tested a group-based cognitive training program for people with schizophrenia who have had the condition for less than 10 years. The program teaches practical strategies to work around memory, attention, and planning problems. Researchers compared the costs and daily f…

This study tested an experimental drug called AVP-786 in 145 people with schizophrenia whose symptoms were not fully controlled by their current medication. The goal was to see if adding AVP-786 could reduce negative symptoms like lack of motivation and social withdrawal. Partici…

This study tested a medicine called iclepertin to see if it could improve memory, attention, and problem-solving in adults with schizophrenia. Over 600 participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medications. Res…

This study looked at how safe and tolerable the drug lumateperone is for teenagers aged 13 to 17 with schizophrenia or schizoaffective disorder. Researchers gave the drug to 26 teens and monitored side effects and how the drug moves through the body. The goal was to gather early …

This early-stage study tested the safety and how the body handles a new drug called MK-8189 (elpipodect) in 63 people. It included younger adults with schizophrenia and older adults with or without schizophrenia. The main goal was to check for side effects and see how the drug mo…

This study tested whether taking part in art activities, like painting or music, can improve mental wellbeing and reduce symptoms of anxiety and depression. 382 people with various mental health issues were randomly assigned to either an art program or a waiting list. The results…

This study tested a visual training program for 79 adults with schizophrenia or schizoaffective disorder. The program aimed to improve two visual skills often impaired in these conditions: seeing contrast and organizing visual information. Participants completed different trainin…

This early-stage study tested an oral medication called brexpiprazole in 43 teenagers aged 13 to 17 with schizophrenia or related disorders. The main goal was to check the drug's safety and how the body processes it, not to measure how well it works. Researchers monitored side ef…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia better than a placebo. 450 adults with worsening psychosis took either the drug or a placebo for 28 days. The main goal was to see if their symptoms improved, measured by a standard psychiatr…

This study tested a new medicine called CVL-231 (Emraclidine) in 391 adults with schizophrenia who were having a sudden worsening of psychotic symptoms. The goal was to see if the drug could reduce symptoms like hallucinations and delusions better than a placebo over 6 weeks. Par…

This study tested a non-invasive brain stimulation technique called rTMS in 85 people with schizophrenia who still had severe hallucinations despite medication. Using MRI scans to precisely target the brain areas involved, the treatment aimed to reduce the strength and frequency …

This study looked at whether a type of talk therapy called Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) works for veterans who also have a serious mental illness like schizophrenia or bipolar disorder. 47 veterans took part to see if the therapy was helpful and practica…

This study tested whether mild electrical stimulation (tDCS and tRNS) applied to the front of the brain could improve thinking and memory in 36 adults with schizophrenia. Participants completed memory and problem-solving tasks after receiving each type of stimulation. The goal wa…

This study tested whether a new drug called ITI-007 can reduce symptoms of schizophrenia during a sudden worsening of psychosis. 335 adults with schizophrenia were randomly assigned to receive ITI-007, a placebo, or another antipsychotic. The main goal was to measure changes in s…

This study tested whether luteolin, a natural substance found in foods like celery and chamomile tea, can improve symptoms of schizophrenia. Researchers gave luteolin or a placebo to 85 adults with schizophrenia or schizoaffective disorder who were already on stable antipsychotic…

This study tested a new drug called MK-8189 (elpipodect) in 499 adults having an acute episode of schizophrenia. The goal was to see if it reduces symptoms like hallucinations and delusions better than a placebo over 6 weeks. The drug was compared to both a placebo and an active …

This study tested a new medicine called iclepertin in 620 adults with schizophrenia to see if it could improve memory and thinking. Participants took either iclepertin or a placebo daily for 26 weeks, while continuing their usual schizophrenia medication. Researchers measured cha…

This study tested whether adding KarXT (a combination of two medicines) to standard antipsychotic treatment helps reduce schizophrenia symptoms that were not well controlled. About 400 adults with schizophrenia took either KarXT or a placebo for 6 weeks. The main goal was to see …

This early-stage study tested TAK-063, an experimental drug, in 77 people (some with stable schizophrenia, some healthy Japanese volunteers). The main goal was to see if the drug is safe and how the body processes it at different doses. No major claims about effectiveness were ma…

This study tested whether adding the drug memantine to a computer-based cognitive training program improves thinking and daily function in people with schizophrenia or schizoaffective disorder. 62 adults took part in a double-blind trial where some received memantine plus trainin…

This study tested a new drug called KarXT in 202 Chinese adults hospitalized with schizophrenia. The goal was to see if KarXT could reduce symptoms like hallucinations and social withdrawal better than a placebo over 5 weeks. After that, everyone could receive KarXT for 12 more w…

This study tested a new drug called CVL-231 (Emraclidine) in 385 people with schizophrenia who were having a sudden worsening of psychotic symptoms. Participants took either a low dose, a high dose, or a placebo daily for 6 weeks. The main goal was to see if the drug reduced symp…

This study tested a light-based treatment called photoneuromodulation for the negative symptoms of schizophrenia (like lack of motivation or social withdrawal). Thirty adults who had not responded to other treatments received either real or sham light therapy, then switched group…

This study tested a 4-week virtual reality (VR) cognitive training program in 62 people with stable mood disorders (depression or bipolar) or psychosis spectrum disorders (like schizophrenia). The program used simulated daily-life challenges to improve thinking and daily function…

This study tested whether adding behavioral skills training to standard job support helps people with schizophrenia keep a job longer. 107 adults took part. The main goal was to see if the extra training increased the total number of weeks worked.

This study tested a new drug called CPL500036 in 189 people with schizophrenia who were having a sudden worsening of symptoms. The goal was to see if the drug could reduce symptoms like hallucinations and delusions over 28 days compared to a placebo. The trial has been completed,…

This study looked at how well valbenazine works for tardive dyskinesia (TD), a condition causing uncontrollable movements often linked to long-term use of certain mental health medications. Fifty-nine adults with schizophrenia, bipolar disorder, or major depression took valbenazi…

This study tested whether a new drug called TAK-063 can help reduce symptoms of schizophrenia during a sudden worsening (acute exacerbation). 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved, measured by a standard rating sca…

This study tested an investigational medication called BXCL501 for calming agitation episodes in people with bipolar disorder, schizophrenia, or related conditions. 452 participants received either the drug or a placebo, and researchers measured changes in agitation levels and sa…

This study looked at how a new drug called MP-214 works in 38 adults with schizophrenia. Researchers measured safety, how the drug moves through the body, and whether it helps control symptoms over 12 weeks. The goal was to find the right dose and check for side effects.

This study tested a behavioral program called Social Cognition Interaction Training (SCIT) to help people with schizophrenia improve their social skills. About 51 participants were randomly assigned to either the training or a waitlist. Researchers measured changes in emotion rec…

This study tested whether delivering mental health services through telehealth (video calls) helps young adults with psychotic disorders stay engaged in care and avoid hospital stays better than standard in-person clinic visits. Seventy-four participants aged 16 to 35 with recent…

This study followed 51 people with schizophrenia who were already stable on long-acting injectable antipsychotics. Over 48 weeks, researchers checked if symptoms returned when patients reliably received their medication. The goal was to see how often relapse happens when adherenc…

This study looked at how young adults aged 18-30 with early psychosis process information about their surroundings, compared to those without a psychiatric diagnosis. Researchers used computer-based tasks and cognitive training to measure changes in thinking skills. The goal was …

This study aims to understand the biological causes of schizophrenia and figure out which symptoms come from the illness itself versus the medications used to treat it. About 648 participants with schizophrenia will stay in a hospital, temporarily stop their medication, and under…

This study used PET scans to watch brain activity while people performed thinking tasks. It included healthy volunteers and people with schizophrenia or Parkinson's disease. The goal was to learn how the frontal lobe works during thinking and how certain drugs might affect it.

This study looked at whether smartphone data—like activity, sleep, and social patterns—could help track symptoms in 87 veterans with serious mental illnesses such as schizophrenia, bipolar disorder, or PTSD. Participants used an app that passively collected this data. The goal wa…

This study checked if a generic 4 mg brexpiprazole tablet works the same as the brand-name drug (Rxulti) in 36 healthy adults aged 45 to 65. Participants took one dose of each drug under fasting conditions, and researchers measured drug levels in the blood to compare them. The go…

This study looked at how people aged 15-45 with early psychosis process information about their surroundings, called state representation. Participants completed computer tasks while their brain activity was measured using EEG and MRI. The goal was to understand brain function di…

This study tested whether sending text message reminders to young people (ages 14-35) who had a first episode of psychosis could help them attend their first appointment at an early psychosis program after being seen in the emergency department. The study involved 186 participant…

This study looked at how the body builds tolerance to Igalmi (a fast-acting medicine for agitation) and what happens when it's stopped. It involved 29 adults with schizophrenia or bipolar disorder who had frequent agitation. Researchers measured changes in agitation levels and wa…

This study tested a program called Collaborative Decision Skills Training (CDST) to help veterans with serious mental illness, like schizophrenia or major depression with psychosis, become more involved in decisions about their care. 39 veterans took part in an initial small tria…

This study looked at 100 Veterans with mental health conditions like schizophrenia, PTSD, anxiety, or mood disorders. The goal was to see if a simple brain wave test (called mismatch negativity) could help match each person to the right type of cognitive training. The approach ai…

This completed study from the National Institute of Mental Health looked at over 4,900 people with schizophrenia or related disorders, along with their siblings. The goal was to find genes linked to the illness and see how they affect brain function. By studying families, researc…

This study looked at how two common schizophrenia medications, risperidone and aripiprazole, affect the energy-producing parts of cells (mitochondria) in 60 patients. The goal was to measure changes in cell energy markers over 12 weeks. The study did not test a new treatment, but…

This study looked at whether a digital training platform helps clinicians use a smartphone app called FOCUS to support people with serious mental illness like schizophrenia or bipolar disorder. 191 adults used the app and received coaching from trained clinicians. The goal was to…

This study tested a new artificial intelligence tool called CBTpro that helps therapists improve their skills in cognitive behavioral therapy for people with psychosis. Over 600 adults with conditions like schizophrenia or bipolar disorder took part. The goal was to see if the to…

This early-stage study tested an experimental drug called MK-8189 (elpipodect) in 55 people, including healthy volunteers and those with schizophrenia. The main goal was to check the drug's safety and how the body absorbs and processes it. Researchers also looked at brain activit…

This study checked the dental health of 110 adults with schizophrenia in Côte d'Or, France. Participants had a mouth exam, a blood test for vitamin C, and answered questions about their dental care and eating habits. The goal was to understand their current dental status, not to …

This study tested a new questionnaire to understand how people with schizophrenia feel about their oral health. Researchers asked 59 patients to fill out surveys about their teeth and quality of life. The goal is to create a reliable tool that can help design better dental preven…

This study looked at how the brain creates the feeling of being in control of our own actions. Researchers compared healthy volunteers with people who have schizophrenia or bipolar disorder, especially those who feel their actions are controlled by an external force. The goal was…

This study looked at whether a memory technique called retrieval practice works in people with schizophrenia. 40 participants (patients and healthy controls) learned word pairs and were tested two days later. The goal was to see if being tested on the words helped them remember b…

This study looked at how teenagers with autism or schizophrenia understand emotions, intentions, and social situations compared to healthy teens. Researchers measured brain activity while participants performed tasks like recognizing facial expressions. The goal was to find out i…

This study tested a new automated phone system called 'My Coach Connect' for people with chronic mental illness, including depression, schizophrenia, and bipolar disorder. Participants called the system twice a week to answer questions about how they were doing, and their respons…

This study tested two types of brain stimulation (TMS) in 90 nicotine users, some with schizophrenia and some without. The goal was to see if the stimulation could change brain connections and reduce cravings for nicotine. Participants completed tasks and reported their cravings …

This study tested two mobile health (mHealth) strategies for people with schizophrenia receiving care at community clinics. About 299 participants used smartphone tools to track symptoms like depression, anxiety, and hallucinations. The goal was to see if these tools could help m…

This study tested a program called Illness Management and Recovery (IMR) for adults with schizophrenia or bipolar disorder. The goal was to see if the program helps improve daily functioning and overall well-being. 198 participants from community mental health centers in Denmark …

This study followed 168 pregnant or breastfeeding women with serious mental health conditions like schizophrenia or mania who were already taking long-acting injectable antipsychotics. Researchers measured drug levels in the mother's blood, breastmilk, and the baby's blood to und…

This study looked at how a drug called quinidine changes the way the body processes SEP-380135, a potential schizophrenia treatment. Twelve healthy adults took a single dose of SEP-380135 with and without quinidine to measure drug levels and safety. The goal was to understand pos…

This pilot study tested a telehealth program called CRAFT-EP for families of people with early psychosis who also use alcohol or cannabis. 65 family members took part to see if the program could improve their wellbeing, including reducing depression and anxiety. The goal was to l…

This study looked at dopamine receptors in the brains of people with schizophrenia and healthy volunteers. Using special PET and MRI scans, researchers measured two types of dopamine receptors to learn more about how schizophrenia develops. The goal was to gather knowledge that c…

This study tested whether customizing cognitive remediation (brain training) based on a person's early auditory processing ability leads to better thinking and daily living skills in people with schizophrenia or schizoaffective disorder. 194 adults from community mental health ce…

This study looked at how people aged 15-45 with early psychosis process information about their surroundings, compared to those without a psychiatric diagnosis. Researchers tested two types of cognitive training and measured changes in thinking and brain activity using computer t…

This study looked at whether cannabis or a cannabis-like drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part, including those with schizophrenia and healthy controls. The goal was to understand if cann…

This study tested a new mobile app called iTEST for people with schizophrenia or schizoaffective disorder. The app trains users to more accurately judge how well they perform on memory and emotion recognition tasks. The goal was to see if improving this self-awareness could lead …

This study used advanced brain scans (MRI and MEG) to compare the brain structure, chemistry, and activity of people with schizophrenia and healthy volunteers. Over 3,200 adults took part. The goal was to better understand the brain changes linked to schizophrenia, not to test a …

This early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Researchers measured side effects, vital signs, and mood chan…

This study looked at how two different speeds of magnetic brain stimulation (slow vs. fast) change brain activity in 30 healthy adults. The goal was to understand how this technique works for treating depression and schizophrenia. Participants received both types of stimulation o…

This study tested whether eating food changes how the body absorbs a new once-weekly version of the schizophrenia drug brexpiprazole. Fifty-nine adults with stable schizophrenia took the drug once with food and once without food, and researchers measured drug levels in their bloo…

This study looked at how a supplement called N-acetylcysteine (NAC) affects brain chemicals and thinking in people with schizophrenia. Researchers gave participants tryptophan (an amino acid) to raise a brain chemical called kynurenic acid, then used cognitive tests and MRI scans…

This study looked at how young people (ages 15-35) with a parent or sibling who has schizophrenia understand social situations and recognize emotions. Researchers used brain scans and emotion recognition tests to see if training programs could help improve these skills. The goal …

This study checked whether a high dose of the experimental drug MK-8189 (elpipodect) causes heart rhythm changes in people with schizophrenia. 107 participants received the drug, a placebo, and an active control in a crossover design. The main goal was to see if the drug's effect…

This study looked at how people with schizophrenia organize memories of everyday events. About 80 participants, including patients and healthy volunteers, took a 1-hour walk in Strasbourg while wearing an automatic camera. Later, they were asked to put photos from the walk in ord…

This study used PET scans to look at dopamine and blood flow in the brains of 502 people, including healthy volunteers and those with Parkinson's disease or schizophrenia. The goal was to understand how dopamine problems affect these conditions. No treatment was given; it was pur…

This study tested whether a program combining education about schizophrenia with motivational interviewing could help patients learn more about their condition and feel more hopeful. 44 adults with schizophrenia who were not in an acute phase took part. The results showed that th…

This study looked at how a non-invasive brain stimulation technique called TMS changes brain activity in people with schizophrenia. Ten participants received both real and fake TMS sessions, and researchers measured brain connectivity and electrical signals before and after. The …

This study looked at whether a program called NAVIGATE helps youth (ages 14-35) having their first episode of psychosis get better coordinated care. Researchers worked with 100 participants across Ontario to see if the program reduces hospital stays and ER visits. The goal was to…

This study tested whether a support group led by trained peers (people who also have schizophrenia) can help patients learn more about their illness and improve their symptoms and daily functioning. Over 300 adults with schizophrenia took part and were followed for two years. The…

This study looked at whether family members or caregivers can help measure agitation in people with bipolar disorder or schizophrenia. 33 adults took a single dose of an experimental medicine, and researchers compared ratings from doctors, patients, and their family members. The …